亿帆医药(002019.SZ)发布上半年业绩，归母净利润3.04亿元，同比增长19.91%

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating positive financial performance despite a modest growth in sales [1] Financial Performance - The company achieved operating revenue of 2.635 billion yuan, representing a year-on-year growth of 0.11% [1] - The net profit attributable to shareholders reached 304 million yuan, showing a year-on-year increase of 19.91% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 237 million yuan, reflecting a year-on-year growth of 32.21% [1] - Basic earnings per share were reported at 0.25 yuan [1]